D. E. Shaw & Co. Inc. Purchases 24,173 Shares of Merrimack Pharmaceuticals Inc (MACK)

D. E. Shaw & Co. Inc. raised its position in Merrimack Pharmaceuticals Inc (NASDAQ:MACK) by 78.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,124 shares of the biopharmaceutical company’s stock after acquiring an additional 24,173 shares during the period. D. E. Shaw & Co. Inc. owned about 0.41% of Merrimack Pharmaceuticals worth $213,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in Merrimack Pharmaceuticals by 54,994.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 55,094 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 54,994 shares in the last quarter. Two Sigma Investments LP raised its holdings in Merrimack Pharmaceuticals by 28.7% in the 4th quarter. Two Sigma Investments LP now owns 72,877 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 16,254 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Merrimack Pharmaceuticals by 22.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 573,514 shares of the biopharmaceutical company’s stock valued at $3,057,000 after acquiring an additional 105,137 shares in the last quarter. 22NW LP acquired a new position in Merrimack Pharmaceuticals in the 4th quarter valued at approximately $2,892,000. Finally, Bank of New York Mellon Corp acquired a new position in Merrimack Pharmaceuticals in the 4th quarter valued at approximately $70,000. 46.20% of the stock is owned by hedge funds and other institutional investors.

In related news, insider Lp 22Nw bought 50,000 shares of the company’s stock in a transaction dated Friday, April 5th. The stock was acquired at an average cost of $6.12 per share, with a total value of $306,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Jfl Capital Management, Llc bought 37,278 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was bought at an average cost of $5.89 per share, with a total value of $219,567.42. The disclosure for this purchase can be found here. Corporate insiders own 9.47% of the company’s stock.

Shares of MACK opened at $5.98 on Wednesday. Merrimack Pharmaceuticals Inc has a 1 year low of $3.34 and a 1 year high of $10.53. The company has a quick ratio of 5.14, a current ratio of 5.14 and a debt-to-equity ratio of 0.25.

Merrimack Pharmaceuticals (NASDAQ:MACK) last issued its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.04.

Separately, ValuEngine raised Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $4.38.

COPYRIGHT VIOLATION NOTICE: “D. E. Shaw & Co. Inc. Purchases 24,173 Shares of Merrimack Pharmaceuticals Inc (MACK)” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.com-unik.info/2019/04/17/d-e-shaw-co-inc-purchases-24173-shares-of-merrimack-pharmaceuticals-inc-mack.html.

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5.

Further Reading: What is Compound Annual Growth Rate (CAGR)?

Want to see what other hedge funds are holding MACK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merrimack Pharmaceuticals Inc (NASDAQ:MACK).

Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit